# Hemochromatosis osteoarthritis

## TL;DR

Hemochromatosis osteoarthritis is a joint disease caused by iron overload, involving bone and cartilage damage, and is managed through treatments like phlebotomy and surgery.

## Contribution

This paper provides a comprehensive overview of hemochromatosis-associated arthropathy, including its diagnosis, treatment, and prevention.

## Key findings

- Hemochromatosis osteoarthritis is primarily a degenerative joint disease with iron-related damage.
- Diagnosis combines imaging and iron function tests, with genetic testing as a supplementary tool.
- Treatment includes phlebotomy, iron chelation, and surgical options.

## Abstract

Hemochromatosis-associated arthropathy is a progressive degenerative joint disease characterized by iron-overload related pathological changes. While it may involve episodic inflammatory flares, it is primarily defined by bone and cartilage destruction rather than persistent chronic synovitis. It is typically classified as either spontaneous or secondary. This condition is often accompanied by various clinical manifestations, including liver disease, cardiomyopathy, skin pigmentation changes, diabetes mellitus, erectile dysfunction, and hypothyroidism. Diagnosis typically relies on a combination of imaging techniques such as x-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, along with iron function tests and joint fluid analysis. Genetic testing may also serve as an adjunctive diagnostic tool. The main treatment modalities currently available include phlebotomy (the primary therapy for hereditary hemochromatosis), iron chelators, joint cavity drug injections, and surgical interventions. Lastly, we delve into the preventative measures that can be adopted to mitigate the risk of developing this disease.